Amivas

Amivas is a commercial-stage biopharmaceutical company established as a transatlantic joint venture to address critical shortages in severe malaria treatment. Its core achievement is the regulatory approval and global commercialization of intravenous Artesunate, which became essential after the discontinuation of quinidine gluconate in 2019. The company has successfully launched the first and only licensed severe malaria treatment in Europe and secured FDA approval in the US, positioning itself as a key supplier to hospitals worldwide. Its mission is to expand its role as a leader in providing critical medicines for life-threatening infectious diseases.

Focused on the development, manufacturing, and global commercialization of a parenteral formulation of the established antimalarial compound Artesunate. Expertise lies in securing API supply, GMP manufacturing of sterile injectables, and navigating global regulatory pathways for critical care medicines.

In its core markets (US, Europe, Australia), Amivas currently holds a monopoly or near-monopoly position as the sole licensed supplier of intravenous Artesunate for severe malaria, following the discontinuation of quinidine. Potential future competition could come from generic entrants or alternative formulations, but the limited market size may act as a barrier to entry.